首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1517751

组织和器官移植市场 - 全球产业规模、份额、趋势、机会和预测，按产品、应用、地区和竞争细分，2019-2029F

Tissue And Organ Transplantation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2019-2029F

出版日期: 2024年07月21日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年全球组织和器官移植市场价值为162.5亿美元，预计在预测期内将稳定成长，到2029年复合年增长率为8.25%。，为人们提供生命-为患有器官衰竭、组织损伤和遗传性疾病的患者提供挽救性治疗。这个充满活力的领域涵盖了旨在恢復器官功能和提高生活品质的广泛医疗程序、技术和疗法。随着医学科技的不断进步，移植市场在满足全球医疗保健需求方面面临机会和挑战。

市场概况
预测期	2025-2029
2023 年市场规模	162.5亿美元
2029 年市场规模	258.6亿美元
2024-2029 年复合年增长率	8.25%
成长最快的细分市场	纸巾产品
最大的市场	北美洲

技术创新彻底改变了组织和器官移植领域，提高了患者的治疗效果并扩大了治疗选择。改进的手术技术，包括微创手术和机器人辅助手术，可以减少移植受者的恢復时间和术后併发症。免疫抑制疗法和个人化医疗的进步使供体器官与受体更好地匹配，最大限度地降低排斥风险并提高长期移植物存活率。

对可移植器官的需求远远超过供应，导致全球范围内等待名单冗长且严重短缺。造成这种不平衡的因素包括人口老化、糖尿病和肾臟病等慢性病盛行率上升以及合适的捐赠器官供应有限。透过公众宣传活动、政策改革和器官保存技术的进步来努力提高器官捐赠率对于应对这项挑战和减少移植受者的等待时间至关重要。

监管框架管理器官采购、移植程序以及围绕捐赠者同意和患者护理的伦理考虑。美国器官共享联合网络（UNOS）和欧洲欧洲移植国际基金会等监管机构制定了器官分配、移植中心认证和资料管理指南，以确保捐赠器官的公平公正分配并维护道德标准在移植实践中。

儘管取得了重大进展，组织和器官移植仍面临一些挑战。这些包括器官短缺、免疫障碍、移植排斥、免疫抑制治疗的併发症以及移植手术和长期照护的高成本。应对这些挑战需要持续投资于研发、医疗保健提供者和监管机构之间的合作以及扩大捐赠者库和改善全球移植结果的创新方法。

随着异种移植（不同物种之间的器官移植）、组织和器官生物工程以及再生医学和干细胞疗法的进步的持续研究，组织和器官移植的未来充满希望。生物列印技术可以使用患者特异性细胞创建 3D 列印组织和器官，从而有可能减少对捐赠器官的依赖并提高移植成功率。此外，人工智慧（AI）和机器学习被用来增强器官匹配演算法、预测患者结果并优化移植方案。

主要市场驱动因素

慢性病盛行率增加

人口老化加剧

主要市场挑战

器官和组织短缺

主要市场趋势

免疫治疗和免疫遗传学的进展

细分市场洞察

产品洞察

应用洞察

区域洞察

Global Tissue And Organ Transplantation Market was valued at USD 16.25 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 8.25% through 2029. The tissue and organ transplantation market plays a vital role in modern medicine, offering life-saving treatments for patients suffering from organ failure, tissue damage, and genetic disorders. This dynamic sector encompasses a wide range of medical procedures, technologies, and therapies aimed at restoring organ function and improving quality of life. As advancements in medical science and technology continue to accelerate, the transplantation market faces both opportunities and challenges in meeting global healthcare needs.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 16.25 Billion
Market Size 2029	USD 25.86 Billion
CAGR 2024-2029	8.25%
Fastest Growing Segment	Tissue Products
Largest Market	North America

Technological innovations have revolutionized the field of tissue and organ transplantation, enhancing patient outcomes and expanding treatment options. Improved surgical techniques, including minimally invasive procedures and robotic-assisted surgeries, reduce recovery times and post-operative complications for transplant recipients. Advances in immunosuppressive therapies and personalized medicine enable better matching of donor organs to recipients, minimizing the risk of rejection and improving long-term graft survival rates.

The demand for transplantable organs far exceeds the supply, resulting in lengthy waiting lists and critical shortages worldwide. Factors contributing to this imbalance include aging populations, rising prevalence of chronic diseases such as diabetes and kidney disease, and limited availability of suitable donor organs. Efforts to increase organ donation rates through public awareness campaigns, policy reforms, and advancements in organ preservation technologies are critical to addressing this challenge and reducing waiting times for transplant recipients.

Regulatory frameworks govern organ procurement, transplantation procedures, and ethical considerations surrounding donor consent and patient care. Regulatory bodies such as the United Network for Organ Sharing (UNOS) in the United States and the Eurotransplant International Foundation in Europe establish guidelines for organ allocation, transplant center accreditation, and data management to ensure fair and equitable distribution of donor organs and uphold ethical standards in transplantation practices.

Despite significant progress, tissue and organ transplantation faces several challenges. These include organ shortage, immunological barriers, transplant rejection, complications from immunosuppressive therapies, and the high cost of transplantation procedures and long-term care. Addressing these challenges requires continued investment in research and development, collaboration between healthcare providers and regulatory bodies, and innovative approaches to expand the donor pool and improve transplant outcomes globally.

The future of tissue and organ transplantation holds promise with ongoing research into xenotransplantation (organ transplantation between different species), bioengineering of tissues and organs, and advancements in regenerative medicine and stem cell therapies. Bio-printing technologies are enabling the creation of 3D-printed tissues and organs using patient-specific cells, potentially reducing reliance on donor organs and improving transplant success rates. Moreover, artificial intelligence (AI) and machine learning are being leveraged to enhance organ matching algorithms, predict patient outcomes, and optimize transplant protocols.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The global tissue and organ transplantation market is witnessing significant growth driven by the increasing prevalence of chronic diseases worldwide. Chronic diseases, characterized by prolonged duration and typically slow progression, include conditions such as end-stage renal disease, cardiovascular diseases, liver cirrhosis, and diabetes mellitus. These conditions often lead to organ failure, necessitating transplantation as a life-saving treatment option for patients who do not respond to other therapies.

According to the data presented by Medscape in 2022, it has been observed that Worldwide, an estimated 152,863 solid organ transplants were performed in 2019. [1] In the United States, 39,000 organ transplantations were performed in 2020. [2] Renal transplants were the most common, followed by those of the liver, heart, lung, and others, including dual organ, pancreatic, and intestinal transplantation. Over the last several decades, the field of solid organ transplantation (SOT) science and practice has advanced significantly, only to be continually challenged by the risks for infection in SOT recipients.

Advancements in surgical techniques, immunosuppressive therapies, and organ preservation methods have significantly improved transplant outcomes and expanded the pool of eligible transplant recipients. Minimally invasive surgical approaches reduce recovery times and improve patient comfort, while innovative organ preservation technologies extend the viability of donor organs, enhancing transplant success rates.

Improvements in healthcare infrastructure and access to specialized transplant centers play a crucial role in meeting the growing demand for transplantation services. Developing countries are investing in transplant infrastructure, medical training, and regulatory frameworks to expand access to transplant procedures and ensure equitable healthcare delivery.

Rising healthcare expenditure, both in developed and emerging economies, supports investment in transplant services, medical technologies, and patient care. Governments and healthcare providers allocate resources to enhance transplant capabilities, improve post-operative care, and address disparities in access to transplantation services based on socioeconomic factors.

Growing Aging Population

The global tissue and organ transplantation market is poised for significant growth driven by the demographic shift towards an aging population. As life expectancy increases worldwide, so does the prevalence of age-related diseases and conditions that necessitate organ and tissue transplantation. This demographic trend presents both opportunities and challenges for healthcare providers, researchers, and policymakers aiming to meet the growing demand for transplantation services.

Advances in healthcare, nutrition, and lifestyle improvements have contributed to longer life expectancies globally. As populations age, the incidence of chronic diseases such as kidney failure, heart disease, and liver cirrhosis increases, often necessitating organ transplantation as a life-saving intervention. Elderly individuals are more susceptible to age-related conditions that affect organ function and integrity. Chronic conditions such as diabetes, hypertension, and cardiovascular diseases can lead to organ failure over time, necessitating transplantation as a treatment option.

The growing aging population contributes to an escalating demand for organs and tissues suitable for transplantation. This demand underscores the need for expanded donor networks, improved organ preservation techniques, and advancements in transplant technologies to meet clinical needs effectively. The economic burden of age-related diseases and organ failure is substantial, encompassing healthcare expenditures related to treatment, hospitalization, and post-transplant care. Organ transplantation offers a cost-effective alternative to prolonged medical management for end-stage organ failure, enhancing quality of life and reducing long-term healthcare costs.

Ongoing research and innovation in biotechnology and medical devices have facilitated improvements in organ preservation, immunosuppressive therapies, and surgical techniques. Innovations such as 3D printing of organs and tissue engineering hold promise for addressing donor shortages and enhancing transplant outcomes. The expansion of transplantation services necessitates robust regulatory frameworks to ensure patient safety, ethical donor practices, and equitable access to transplantation. Regulatory agencies worldwide play a pivotal role in overseeing clinical trials, approving new therapies, and safeguarding ethical standards in organ procurement and allocation.

Key Market Challenges

Shortage of Organs and Tissues

The shortage of organs and tissues represents a formidable challenge in the global tissue and organ transplantation market, impacting millions of patients worldwide awaiting life-saving treatments. This shortage, driven by several complex factors, poses significant barriers to meeting the growing demand for transplantation procedures and improving patient outcomes. One of the primary issues contributing to the shortage is the stark disparity between the demand for transplantable organs and tissues and their availability. According to global health organizations, including the World Health Organization (WHO) and the Organ Procurement and Transplantation Network (OPTN), the number of patients on waiting lists for organs far exceeds the number of organs available for transplantation each year. This disparity is particularly acute for organs such as kidneys, livers, hearts, and lungs, which are essential for treating end-stage organ failure and life-threatening conditions.

Donor recruitment remains a significant challenge in addressing the shortage of organs and tissues. Organ donation relies heavily on voluntary donors and their families consenting to donate organs after death or, in the case of living donors, donating a portion of their organs such as kidneys or liver segments. Factors influencing donor recruitment include cultural beliefs, religious considerations, public awareness about organ donation, and the sensitivity of end-of-life discussions. Increasing donor registration rates and improving public education about the benefits of organ donation are crucial steps toward expanding the donor pool and alleviating shortages.

Logistical challenges in organ procurement and transportation further exacerbate the shortage issue. Organs must be carefully matched to recipients based on immunological compatibility and transported under strict conditions to ensure viability and safety. This process involves coordination among medical teams, transplant centers, and transportation services, adding complexity and potential delays to the transplantation process. Moreover, ethical considerations surrounding organ allocation, equitable access to transplantation services, and ensuring fair distribution of organs across regions and demographics require careful management and adherence to regulatory guidelines.

Addressing the shortage of organs and tissues requires global collaboration among healthcare providers, policymakers, researchers, and patient advocacy groups. International efforts to harmonize organ procurement practices, improve transplantation infrastructure, and establish ethical guidelines for organ donation and allocation are essential. Governments play a critical role in promoting organ donation awareness campaigns, enhancing transplant infrastructure, and incentivizing healthcare systems to prioritize transplantation as a viable treatment option.

Key Market Trends

Advances in Immunotherapy and Immunogenetics

Immunotherapy has emerged as a groundbreaking approach in tissue and organ transplantation by modulating immune responses to promote tolerance and minimize rejection. Traditional immunosuppressive therapies, while effective, pose risks such as increased susceptibility to infections and long-term organ damage. The development of targeted immunotherapies aims to mitigate these risks by selectively suppressing immune responses against transplanted tissues while preserving overall immune function.

Cutting-edge immunotherapeutic strategies include the use of monoclonal antibodies, immune checkpoint inhibitors, and adoptive cell therapies. These therapies are designed to regulate specific immune pathways involved in rejection reactions, thereby improving graft survival rates and reducing the need for long-term immunosuppression. Advances in precision medicine have enabled personalized approaches to immunotherapy, tailoring treatments based on individual immune profiles and genetic factors.

In March 2024, Researchers at the Wyss Institute at Harvard University and Harvard's John A. Paulson School of Engineering and Applied Sciences (SEAS) have made significant strides in neutrophil therapies. Neutrophils have long been utilized to bolster the immune systems of cancer patients undergoing chemotherapy. However, the novel approach of using neutrophils to directly target cancer itself marks a pioneering advancement. The team developed disc-shaped micropatches attached to neutrophils, enabling these cells to sustain their anti-tumor (N1) state, yielding promising results in mouse models.

Unlike previous methods where stimulatory molecules were loaded into backpacks and delivered into immune cells to activate them, our latest research revealed that simply attaching empty backpacks to neutrophils is sufficient to activate them. This discovery enhances the appeal of this technique as a 'drug-free' cell therapy for cancer.

Immunogenetics plays a crucial role in optimizing donor-recipient matching to minimize immune rejection in transplantation. Genetic compatibility between donors and recipients, particularly in human leukocyte antigen (HLA) systems, influences transplant outcomes significantly. High-resolution HLA typing and advanced genomic sequencing technologies have enhanced the accuracy of matching algorithms, increasing the likelihood of successful transplantations and reducing rejection rates.

Furthermore, innovations in genomics and bioinformatics have facilitated the identification of additional genetic markers beyond HLA, such as minor histocompatibility antigens and cytokine polymorphisms. These markers provide insights into immune responses and help predict individual predispositions to rejection or tolerance induction post-transplantation.

Several factors drive the integration of immunotherapy and immunogenetics into the tissue and organ transplantation market. Rising demand for transplantation procedures, coupled with shortages in donor organs, underscores the need for strategies that enhance graft survival and expand donor eligibility. Government initiatives and healthcare policies promoting organ donation and transplantation further stimulate market growth and innovation in immunological therapies.

Moreover, increasing investment in biotechnological research and development fosters the discovery of novel immunotherapeutic targets and biomarkers. Collaborations between academic institutions, biotechnology firms, and pharmaceutical companies drive clinical trials and the commercialization of innovative immunological therapies worldwide.

Looking ahead, the convergence of immunotherapy with emerging technologies, such as artificial intelligence and gene editing tools like CRISPR-Cas9, holds transformative potential in optimizing transplant outcomes and advancing precision medicine approaches. These technological synergies are poised to drive further innovations in immunotherapy and immunogenetics, shaping a future where tissue and organ transplantation become safer, more effective, and more accessible worldwide.

Segmental Insights

Product Insights

Based on Product, Tissue Products have emerged as the fastest growing segment in the Global Tissue And Organ Transplantation Market in 2023. Advancements in tissue engineering, regenerative medicine, and biotechnology have transformed the landscape of tissue products in transplantation. Innovations such as decellularization techniques, which remove cellular components from donor tissues while preserving structural integrity and bioactivity, enable the development of acellular tissue matrices used in reconstructive surgeries and regenerative therapies. Bioengineering approaches allow for the fabrication of tissue constructs using patient-specific cells and biomaterials, promoting tissue regeneration and minimizing immunological rejection.

Tissue products find applications across multiple medical specialties, including orthopedics, dermatology, ophthalmology, neurology, and plastic surgery. In orthopedic procedures, bone grafts and cartilage implants derived from donor tissues or synthetic materials facilitate bone healing and joint reconstruction. Dermatological applications involve skin grafts and wound dressings to promote wound closure and tissue regeneration. Corneal transplants restore vision in patients with corneal diseases, while nerve grafts aid in repairing damaged nerves and restoring sensory function.

The tissue and organ transplantation market is expanding globally, driven by increasing healthcare expenditures, advancements in healthcare infrastructure, and rising patient awareness about treatment options. Developed regions such as North America and Europe lead in tissue product adoption, supported by well-established healthcare systems, reimbursement policies, and research institutions. Emerging markets in Asia-Pacific, Latin America, and the Middle East are witnessing rapid growth in transplantation services, driven by improving access to healthcare, rising disposable incomes, and government initiatives to enhance healthcare delivery.

Application Insights

Based on Application, Organ Transplantation have emerged as the dominating segment in the Global Tissue And Organ Transplantation Market during the forecast period. Organ transplantation remains the definitive treatment for end-stage organ failure, offering patients a chance to regain health, functionality, and quality of life. Whether due to chronic diseases, congenital defects, or acute injuries, organ failure necessitates transplantation when other medical interventions fail to sustain life or function adequately. Kidney transplants, liver transplants, heart transplants, lung transplants, and pancreas transplants are among the most common procedures performed globally.

Advancements in surgical techniques and immunosuppressive therapies have significantly enhanced the success rates of organ transplants. Minimally invasive surgical approaches reduce recovery times and improve patient outcomes, while precise immunosuppressive regimens minimize the risk of organ rejection. These advancements have expanded the eligibility criteria for transplant recipients and increased the longevity of transplanted organs, contributing to the market's growth.

Technological innovations in organ preservation have revolutionized transplantation procedures. Methods such as hypothermic machine perfusion and normothermic organ preservation allow organs to be maintained outside the body for longer periods, optimizing organ viability and transplant success. These advancements have mitigated logistical challenges associated with organ transportation and expanded the geographic reach of transplant centers.

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Tissue And Organ Transplantation Market in 2023. North America boasts a network of specialized transplant centers equipped with state-of-the-art facilities and highly skilled healthcare professionals. These centers offer comprehensive care spanning organ procurement, transplantation surgeries, post-operative management, and long-term follow-up, ensuring optimal patient outcomes.

The region leads in technological innovation across various facets of transplantation medicine, including organ preservation techniques, immunosuppressive therapies, and regenerative medicine. Advanced medical devices, precision medicine approaches, and digital health technologies enhance treatment efficacy and patient safety.

North America hosts some of the world's leading research institutions, universities, and academic medical centers dedicated to transplantation research. These institutions drive innovation through collaborative research endeavors, clinical trials, and interdisciplinary approaches that advance understanding and treatment of transplant-related diseases.

Robust investment in biomedical research and biotechnology innovation fuels R&D efforts in transplantation. Government funding, private sector investments, and philanthropic initiatives support breakthrough discoveries, technology transfer, and commercialization of novel therapies.

Key Market Players

Artivion, Inc

Folio Biosciences LLC

Arthrex, Inc.

Abbvie Inc.

Zimmer Biomet Holdings, Inc.

India Medtronic Private Limited

Novartis AG

Stryker Corporation

BiolifeSolutions Inc.

Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Tissue And Organ Transplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue And Organ Transplantation Market, By Product:

Tissue Products Preservation Solutions Immunosuppressive Drugs

Tissue And Organ Transplantation Market, By Application:

Organ Transplantation Tissue Transplantation

Tissue And Organ Transplantation Market, By Region:

United States
Canada
Mexico

France
United Kingdom
Italy
Germany
Spain

China
India
Japan
Australia
South Korea

Brazil
Argentina
Colombia

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue And Organ Transplantation Market.

Available Customizations:

Global Tissue And Organ Transplantation Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Tissue And Organ Transplantation Market

5. Global Tissue And Organ Transplantation Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Tissue Products, Preservation Solutions, Immunosuppressive Drugs)
- 5.2.2. By Application (Organ Transplantation, Tissue Transplantation)
- 5.2.3. By Region
- 5.2.4. By Company (2023)
5.3. Market Map

6. Asia Pacific Tissue And Organ Transplantation Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Tissue And Organ Transplantation Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Application
- 6.3.2. India Tissue And Organ Transplantation Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Application
- 6.3.3. Australia Tissue And Organ Transplantation Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Application
- 6.3.4. Japan Tissue And Organ Transplantation Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Product
    - 6.3.4.2.2. By Application
- 6.3.5. South Korea Tissue And Organ Transplantation Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Product
    - 6.3.5.2.2. By Application

7. Europe Tissue And Organ Transplantation Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Tissue And Organ Transplantation Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Application
- 7.3.2. Germany Tissue And Organ Transplantation Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Application
- 7.3.3. Spain Tissue And Organ Transplantation Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Tissue And Organ Transplantation Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Application
- 7.3.5. United Kingdom Tissue And Organ Transplantation Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Application

8. North America Tissue And Organ Transplantation Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Tissue And Organ Transplantation Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Application
- 8.3.2. Mexico Tissue And Organ Transplantation Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Application
- 8.3.3. Canada Tissue And Organ Transplantation Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Application

9. South America Tissue And Organ Transplantation Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Tissue And Organ Transplantation Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Tissue And Organ Transplantation Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Tissue And Organ Transplantation Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Application

10. Middle East and Africa Tissue And Organ Transplantation Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Tissue And Organ Transplantation Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Tissue And Organ Transplantation Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Tissue And Organ Transplantation Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Tissue And Organ Transplantation Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Artivion, Inc
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
15.2. Folio Biosciences LLC
15.3. Arthrex, Inc.
15.4. Abbvie Inc.
15.5. Zimmer Biomet Holdings, Inc.
15.6. India Medtronic Private Limited
15.7. Novartis AG
15.8. Stryker Corporation
15.9. BiolifeSolutions Inc.
15.10. Teva Pharmaceutical Industries Ltd.